Sexual Function in Men with Lower Urinary Tract Symptoms and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia: Results of a 6-Month, Randomized, Double-Blind, Placebo-Controlled Study of Tadalafil Coadministered with Finasteride
Authors:
- 1 January 2015
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Sexual Medicine
- Vol. 12 (1) , 129-138
Abstract
Tadalafil (TAD) 5 mg coadministered with finasteride (FIN) 5 mg significantly improves lower urinary tract symptoms (LUTS) in men with benign prostatic hyperplasia (BPH) and prostatic enlargement. However, its effects on erectile/sexual function have yet to be fully described. Assess the effects of TAD/FIN coadministration (compared with placebo [PBO]/FIN) on erectile and sexual function in sexually active men with LUTS and prostatic enlargement secondary to BPH with or without baseline comorbid erectile dysfunction (ED). A randomized, double‐blind, PBO‐controlled study of 695 men (610 sexually active; 450 with baseline ED; 404 sexually active with baseline ED) conducted at 70 sites in 13 countries. TAD 5 mg or PBO once daily coadministered with FIN 5 mg once daily for 26 weeks. International Index of Erectile Function (IIEF) domain and single‐item scores; proportions of patients who demonstrated minimal clinically important differences (MCIDs) in IIEF‐Erectile Function domain scores (IIEF‐EF; MCID defined as ≥4‐point improvement); and sexual dysfunction adverse events (AEs). Compared with PBO/FIN, TAD/FIN resulted in improvements for all IIEF domain and single‐item scores assessed among patients with baseline ED (P ≤ 0.002 for all measures) and among patients without baseline ED (P ≤ 0.041 for all measures). Compared with PBO/FIN, significantly larger percentages of sexually active men with baseline ED treated with TAD/FIN achieved an IIEF‐EF MCID after 4, 12, and 26 weeks of therapy (P < 0.001 for odds ratio comparisons between TAD/FIN and PBO/FIN at all 3three postbaseline timepoints). The incidence of sexual AEs was low: five TAD/FIN patients and seven PBO/FIN patients reported sexual AEs, including ED, decreased/lost libido, and ejaculation disorders. TAD/FIN coadministration for the treatment of men with LUTS and prostatic enlargement secondary to BPH concurrently leads to statistically significant improvements in erectile/sexual function and is well‐tolerated, regardless of the presence/absence of ED at treatment initiation. Glina S, Roehrborn CG, Esen A, Plekhanov A, Sorsaburu S, Henneges C, Büttner H, and Viktrup L. Sexual function in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia: Results of a 6‐month, randomized, double‐blind, placebo‐controlled study of tadalafil coadministered with finasteride. J Sex Med 2015;12:129–138.Keywords
This publication has 17 references indexed in Scilit:
- Efficacy and Safety of the Coadministration of Tadalafil Once Daily with Finasteride for 6 Months in Men with Lower Urinary Tract Symptoms and Prostatic Enlargement Secondary to Benign Prostatic HyperplasiaJournal of Urology, 2014
- EAU Guidelines on the Treatment and Follow-up of Non-neurogenic Male Lower Urinary Tract Symptoms Including Benign Prostatic ObstructionEuropean Urology, 2013
- 1092 Combination therapy with dutasteride and tadalafil in men with moderate-to-severe benign prostatic hyperplasiaEuropean Urology Supplements, 2013
- Minimal Clinically Important Differences in the Erectile Function Domain of the International Index of Erectile Function ScaleEuropean Urology, 2011
- The Effects of Combination Therapy with Dutasteride and Tamsulosin on Clinical Outcomes in Men with Symptomatic Benign Prostatic Hyperplasia: 4-Year Results from the CombAT StudyEuropean Urology, 2010
- The Effects of Dutasteride, Tamsulosin and Combination Therapy on Lower Urinary Tract Symptoms in Men With Benign Prostatic Hyperplasia and Prostatic Enlargement: 2-Year Results From the CombAT StudyJournal of Urology, 2008
- The Long-Term Effect of Doxazosin, Finasteride, and Combination Therapy on the Clinical Progression of Benign Prostatic HyperplasiaNew England Journal of Medicine, 2003
- Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trialUrology, 2003
- The Effect of Finasteride on the Risk of Acute Urinary Retention and the Need for Surgical Treatment among Men with Benign Prostatic HyperplasiaNew England Journal of Medicine, 1998
- The Efficacy of Terazosin, Finasteride, or Both in Benign Prostatic HyperplasiaNew England Journal of Medicine, 1996